入射(几何)
医学
流体衰减反转恢复
胶质母细胞瘤
肿瘤科
对比度(视觉)
内科学
放射科
磁共振成像
癌症研究
物理
光学
作者
Yae Won Park,Geon Jang,Si Been Kim,Kaeum Choi,Kyunghwa Han,Na‐Young Shin,Sung Soo Ahn,Jong Hee Chang,Se Hoon Kim,Seung‐Koo Lee,Rajan Jain
出处
期刊:Neuro-oncology
[Oxford University Press]
日期:2024-05-31
被引量:2
标识
DOI:10.1093/neuonc/noae091
摘要
Abstract Background The incidence of leptomeningeal metastases (LM) has been reported diversely. This study aimed to investigate the incidence, risk factors, and prognosis of LM in patients with isocitrate dehydrogenase (IDH)-wildtype glioblastoma. Methods A total of 828 patients with IDH-wildtype glioblastoma were enrolled between 2005 and 2022. Baseline preoperative MRI including post-contrast fluid-attenuated inversion recovery (FLAIR) was used for LM diagnosis. Qualitative and quantitative features, including distance between tumor and subventricular zone (SVZ) and tumor volume by automatic segmentation of the lateral ventricles and tumor, were assessed. Logistic analysis of LM development was performed using clinical, molecular, and imaging data. Survival analysis was performed. Results The incidence of LM was 11.4%. MGMTp unmethylation (odds ratio [OR] = 1.92, P = .014), shorter distance between tumor and SVZ (OR = 0.94, P = .010), and larger contrast-enhancing tumor volume (OR = 1.02, P < .001) were significantly associated with LM. The overall survival (OS) was significantly shorter in patients with LM than in those without (log-rank test; P < .001), with median OS of 12.2 and 18.5 months, respectively. The presence of LM remained an independent prognostic factor for OS in IDH-wildtype glioblastoma (hazard ratio = 1.42, P = .011), along with other clinical, molecular, imaging, and surgical prognostic factors. Conclusions The incidence of LM is high in patients with IDH-wildtype glioblastoma, and aggressive molecular and imaging factors are correlated with LM development. The prognostic significance of LM based on post-contrast FLAIR imaging suggests the acknowledgment of post-contrast FLAIR as a reliable diagnostic tool for clinicians.
科研通智能强力驱动
Strongly Powered by AbleSci AI